Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid ...

Simpson Manufacturing Co., Inc. (the "Company") (NYSE: SSD), an industry leader in engineered structural connectors and ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Furthermore, a need for manufacturing reliability in an increasingly uncertain geopolitical environment is pushing more companies to examine manufacturing closer to home. Unfortunately ...

In 2024, China's industrial landscape has witnessed a series of exciting "firsts" and groundbreaking achievements which reflect the robust momentum of China's manufacturing sector and underscore ...